Provided by Tiger Trade Technology Pte. Ltd.

Akari Therapeutics PLC

8.24
-0.2160-2.55%
Volume:10.63K
Turnover:89.63K
Market Cap:14.43M
PE:-0.31
High:8.76
Open:8.48
Low:8.05
Close:8.46
52wk High:49.60
52wk Low:3.02
Shares:1.75M
Float Shares:694.50K
Volume Ratio:0.43
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-26.9141
EPS(LYR):-20.5537
ROE:-155.28%
ROA:-17.97%
PB:1.00
PE(LYR):-0.40

Loading ...

Company Profile

Company Name:
Akari Therapeutics PLC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
6
Office Location:
401 East Jackson Street,Suite 3300,Tampa,Florida,United States
Zip Code:
33602
Fax:
929 274 7553
Introduction:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Directors

Name
Position
Abizer Gaslightwala
Chief Executive Officer,Director and President
Hoyoung Huh
Chairman of the Board
James Neal
Independent Director
Ray Prudo
Independent Director
Robert Bazemore
Independent Director
Samir R. Patel
Independent Director
Sandip I. Patel
Independent Director

Shareholders

Name
Position
Abizer Gaslightwala
Chief Executive Officer,Director and President
Kameel Farag
Interim Chief Financial Officer